GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (HKSE:04332) » Definitions » Forward PE Ratio

Amgen (HKSE:04332) Forward PE Ratio : 12.21 (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Amgen Forward PE Ratio?

Amgen's Forward PE Ratio for today is 12.21.

Amgen's PE Ratio without NRI for today is 12.35.

Amgen's PE Ratio for today is 17.99.


Amgen Forward PE Ratio Historical Data

The historical data trend for Amgen's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Forward PE Ratio Chart

Amgen Annual Data
Trend 2016-10 2017-12 2018-12 2019-12 2020-12 2021-12 2022-12 2023-12 2024-04
Forward PE Ratio
4.66 4.43 8.70 8.08 14.06 13.19 13.09 12.11 12.25

Amgen Quarterly Data
2017-09 2017-12 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 4.42 4.43 9.39 8.94 8.70 9.06 9.34 8.27 8.08 8.31 14.33 14.06 14.18 14.58 13.44 13.19 13.28 13.26 12.72 13.09 13.25 13.35 12.06 12.11 12.18

Competitive Comparison of Amgen's Forward PE Ratio

For the Drug Manufacturers - General subindustry, Amgen's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Forward PE Ratio falls into.



Amgen Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Amgen  (HKSE:04332) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Amgen Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Amgen's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (HKSE:04332) Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (HKSE:04332) Headlines

No Headlines